Trial · NCT02500979
Results by group30
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 30
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Efficacy of Pramlintide by Measurement of 24-hour Tissue Mean Weighted Glucose (MWG) Obtained With Continuous Glucose Monitoring (CGM) | Placebo & Regular Insulin | 173.8 | Standard Error 8.17 | mg/dL | |
| Efficacy of Pramlintide by Measurement of 24-hour Tissue Mean Weighted Glucose (MWG) Obtained With Continuous Glucose Monitoring (CGM) | Pramlintide & Regular Insulin | 152.2 | Standard Error 8.17 | mg/dL | |
| Efficacy of Pramlintide by Measurement of Absolute Plasma Glucose Area Under the Plasma Concentration-time Curve (AUC) Following Lunch | Placebo & Regular Insulin | 36.233 | 95% Confidence Interval 31.427 to 41.039 | mmol/L*h | |
| Efficacy of Pramlintide by Measurement of Absolute Plasma Glucose Area Under the Plasma Concentration-time Curve (AUC) Following Lunch | Pramlintide & Regular Insulin | 28.336 | 95% Confidence Interval 23.487 to 33.185 | mmol/L*h | |
| Efficacy of Pramlintide by Measurement of Absolute Plasma Glucose Area Under the Plasma Concentration-time Curve (AUC) Following Dinner | Placebo & Regular Insulin | 23.247 | 95% Confidence Interval 20.472 to 26.021 | mmol/L*h | |
| Efficacy of Pramlintide by Measurement of Absolute Plasma Glucose Area Under the Plasma Concentration-time Curve (AUC) Following Dinner | Pramlintide & Regular Insulin | 17.970 | 95% Confidence Interval 15.231 to 20.709 | mmol/L*h | |
| Efficacy of Pramlintide by Measurement of Absolute Plasma Glucose Area Under the Plasma Concentration-time Curve (AUC) Following Breakfast | Placebo & Regular Insulin | 23.535 | 95% Confidence Interval 20.817 to 26.253 | mmol/L*h | |
| Efficacy of Pramlintide by Measurement of Absolute Plasma Glucose Area Under the Plasma Concentration-time Curve (AUC) Following Breakfast | Pramlintide & Regular Insulin | 19.101 | 95% Confidence Interval 16.280 to 21.922 | mmol/L*h | |
| Efficacy of Pramlintide by Measurement of Incremental 24-hour Tissue Glucose Area Under the Plasma Concentration-time Curve (AUC) Obtained With Continuous Glucose Monitoring (CGM) | Placebo & Regular Insulin | 26243 | Standard Error 3379.8 | mg/dL*min | |
| Efficacy of Pramlintide by Measurement of Incremental 24-hour Tissue Glucose Area Under the Plasma Concentration-time Curve (AUC) Obtained With Continuous Glucose Monitoring (CGM) | Pramlintide & Regular Insulin | -2489 | Standard Error 3379.8 | mg/dL*min | |
| Efficacy of Pramlintide by Measurement of Absolute 24-hour Plasma Glucose Area Under the Plasma Concentration-time Curve (AUC) | Placebo & Regular Insulin | 243.835 | 95% Confidence Interval 220.032 to 267.638 | mmol/L*h | |
| Efficacy of Pramlintide by Measurement of Absolute 24-hour Plasma Glucose Area Under the Plasma Concentration-time Curve (AUC) | Pramlintide & Regular Insulin | 215.417 | 95% Confidence Interval 191.614 to 239.220 | mmol/L*h | |
| Efficacy of Pramlintide by Measurement of Incremental 24-hour Plasma Glucose Area Under the Plasma Concentration-time Curve (AUC) | Placebo & Regular Insulin | 11.181 | Standard Deviation 67.6648 | mmol/L*h | |
| Efficacy of Pramlintide by Measurement of Incremental 24-hour Plasma Glucose Area Under the Plasma Concentration-time Curve (AUC) | Pramlintide & Regular Insulin | -12.753 | Standard Deviation 70.0174 | mmol/L*h | |
| Efficacy of Pramlintide Measured by Percent Time Spent in the Range of >70 mg/dL to <180 mg/dL Tissue Glucose Obtained With Continuous Glucose Monitoring (CGM) | Placebo & Regular Insulin | 43.8 | 95% Confidence Interval 33.6 to 56.9 | Percentage of time | |
| Efficacy of Pramlintide Measured by Percent Time Spent in the Range of >70 mg/dL to <180 mg/dL Tissue Glucose Obtained With Continuous Glucose Monitoring (CGM) | Pramlintide & Regular Insulin | 57.2 | 95% Confidence Interval 44.0 to 74.4 | Percentage of time | |
| Efficacy of Pramlintide by Measurement of Absolute 24-hour Plasma Glucagon Area Under the Plasma Concentration-time Curve (AUC) | Placebo & Regular Insulin | 506.265 | 95% Confidence Interval 459.096 to 558.280 | h*pmol/L | |
| Efficacy of Pramlintide by Measurement of Absolute 24-hour Plasma Glucagon Area Under the Plasma Concentration-time Curve (AUC) | Pramlintide & Regular Insulin | 481.633 | 95% Confidence Interval 436.759 to 531.118 | h*pmol/L | |
| Efficacy of Pramlintide by Measurement of Incremental 24-hour Plasma Glucagon Area Under the Plasma Concentration-time Curve (AUC) | Placebo & Regular Insulin | -14.954 | Standard Deviation 58.9024 | pmol/L*h | |
| Efficacy of Pramlintide by Measurement of Incremental 24-hour Plasma Glucagon Area Under the Plasma Concentration-time Curve (AUC) | Pramlintide & Regular Insulin | -16.055 | Standard Deviation 69.2684 | pmol/L*h |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02500979/results